Kezar Life Sciences (NASDAQ:KZR) Price Target Lowered to $9.00 at Wells Fargo & Company

Kezar Life Sciences (NASDAQ:KZR) had its price objective cut by Wells Fargo & Company from $11.00 to $9.00 in a research report report published on Thursday morning,Benzinga reports. They currently have an equal weight rating on the stock.

Several other research firms also recently issued reports on KZR. HC Wainwright reaffirmed a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, December 2nd. William Blair restated a “market perform” rating on shares of Kezar Life Sciences in a research note on Wednesday, November 13th.

Kezar Life Sciences Trading Down 0.8 %

Shares of KZR stock traded down $0.05 during trading hours on Thursday, reaching $6.47. 3,712 shares of the stock traded hands, compared to its average volume of 72,421. Kezar Life Sciences has a 1-year low of $5.20 and a 1-year high of $11.35. The business has a fifty day moving average price of $7.46 and a 200 day moving average price of $6.74. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $47.21 million, a PE ratio of -0.49 and a beta of 0.25.

Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($2.78) earnings per share for the quarter, beating the consensus estimate of ($3.03) by $0.25. On average, equities research analysts forecast that Kezar Life Sciences will post -5.17 EPS for the current year.

Hedge Funds Weigh In On Kezar Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC acquired a new position in shares of Kezar Life Sciences in the second quarter valued at approximately $630,000. Acuitas Investments LLC raised its stake in shares of Kezar Life Sciences by 42.8% during the 2nd quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock worth $592,000 after purchasing an additional 295,956 shares during the period. Ikarian Capital LLC raised its stake in Kezar Life Sciences by 23.0% in the 3rd quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock valued at $827,000 after acquiring an additional 200,000 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in Kezar Life Sciences in the 2nd quarter valued at about $63,000. Finally, Geode Capital Management LLC grew its holdings in Kezar Life Sciences by 15.0% during the 3rd quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock valued at $485,000 after buying an additional 81,678 shares in the last quarter. 67.90% of the stock is owned by institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.